Evolving Treatment Landscape of
HER2
NSCLC
trastuzumab
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Feb 2023
17 Feb 2023
Historique:
received:
19
01
2023
revised:
14
02
2023
accepted:
15
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Successful targeting of
Identifiants
pubmed: 36831628
pii: cancers15041286
doi: 10.3390/cancers15041286
pmc: PMC9954068
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Mol Cancer Ther. 2020 Sep;19(9):1833-1843
pubmed: 32669315
JAMA Oncol. 2022 Apr 01;8(4):1-4
pubmed: 35113160
Cancer Cell. 2019 Oct 14;36(4):444-457.e7
pubmed: 31588020
Lab Invest. 2022 Oct;102(10):1101-1108
pubmed: 35595825
Cancer Res. 2021 Oct 15;81(20):5311-5324
pubmed: 34380634
Nat Cancer. 2022 Jul;3(7):785-786
pubmed: 35883002
Cancer Discov. 2020 May;10(5):674-687
pubmed: 32213539
Mol Cancer Ther. 2019 Oct;18(10):1721-1730
pubmed: 31292166
J Clin Oncol. 2022 Mar 1;40(7):710-718
pubmed: 34843401
J Clin Oncol. 2020 Aug 20;38(24):2753-2761
pubmed: 32614698
Clin Lung Cancer. 2023 Mar;24(2):e65-e68
pubmed: 36528522
Nat Commun. 2020 Jan 30;11(1):603
pubmed: 32001676
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
Oncologist. 2022 Mar 28;27(Suppl 1):S3-S4
pubmed: 35348784
J Clin Oncol. 2013 Jun 1;31(16):1997-2003
pubmed: 23610105
Clin Cancer Res. 2014 Sep 1;20(17):4436-41
pubmed: 24879797
Clin Cancer Res. 2023 Jan 4;29(1):174-182
pubmed: 36074155
Eur J Cancer. 2022 Feb;162:99-106
pubmed: 34959152
Cancer Discov. 2020 May;10(5):688-701
pubmed: 32213540
Cancer Treat Rev. 2022 May;106:102393
pubmed: 35472631
Ther Adv Med Oncol. 2022 Mar 02;14:17588359221082339
pubmed: 35251321
J Clin Oncol. 2023 Feb 1;41(4):816-825
pubmed: 36379002
J Thorac Oncol. 2020 Apr;15(4):628-636
pubmed: 31945494
Clin Cancer Res. 2022 Jun 29;:OF1-OF10
pubmed: 35766963
Clin Cancer Res. 2021 Mar 1;27(5):1463-1475
pubmed: 33355298
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108
pubmed: 27026201
N Engl J Med. 2022 Jan 20;386(3):241-251
pubmed: 34534430
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
Transl Lung Cancer Res. 2021 Aug;10(8):3659-3670
pubmed: 34584864
NPJ Precis Oncol. 2023 Jan 11;7(1):5
pubmed: 36631624
Clin Cancer Res. 2019 Jan 1;25(1):64-72
pubmed: 30206164
Nat Med. 2022 Sep;28(9):1840-1847
pubmed: 35941372
Cancer. 2019 Dec 15;125(24):4380-4387
pubmed: 31469421
ESMO Open. 2022 Feb;7(1):100395
pubmed: 35149428
Neuro Oncol. 2023 Jan 5;25(1):157-166
pubmed: 35639825
JTO Clin Res Rep. 2022 Oct 29;3(12):100427
pubmed: 36426286
Breast Cancer Res Treat. 2021 Feb;185(3):879-881
pubmed: 33128191
Transl Lung Cancer Res. 2021 Feb;10(2):753-765
pubmed: 33718019
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34376553
Oncoimmunology. 2017 Jul 26;6(11):e1356145
pubmed: 29147605
J Clin Oncol. 2018 Aug 20;36(24):2532-2537
pubmed: 29989854
Cancer Res. 2022 Apr 15;82(8):1633-1645
pubmed: 35149586
J Thorac Oncol. 2018 Feb;13(2):273-279
pubmed: 29313813
JCO Precis Oncol. 2022 Oct;6:e2200278
pubmed: 36240473
Nat Cancer. 2022 Jul;3(7):821-836
pubmed: 35883003
Cancer Discov. 2022 May 2;12(5):1233-1247
pubmed: 35135829
Pharmaceuticals (Basel). 2021 Dec 14;14(12):
pubmed: 34959700
Cancer Cell. 2018 May 14;33(5):922-936.e10
pubmed: 29763625
Clin Lung Cancer. 2021 Jul;22(4):253-259
pubmed: 33582070
J Thorac Oncol. 2018 Dec;13(12):1884-1896
pubmed: 30267840
Cancer Discov. 2022 Dec 2;12(12):2754-2762
pubmed: 36255231
Lung Cancer. 2021 Oct;160:50-58
pubmed: 34403912
J Thorac Oncol. 2021 Nov;16(11):1952-1958
pubmed: 34245914
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
J Thorac Oncol. 2021 Aug;16(8):1267-1288
pubmed: 33915248
Cancer Immun. 2012;12:12
pubmed: 22896757
J Clin Oncol. 2022 Mar 1;40(7):702-709
pubmed: 34550757